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Web-based conferencesThe importance of hormone receptor status in assigning treatment and the potential use of human
epidermal growth factor receptor 2 (HER2)–targeted therapy have made it beneﬁcial for laboratories to
improve detection techniques. Because interlaboratory variability in immunohistochemistry (IHC) tests may
also affect studies of breast cancer subtypes in different countries, we undertook a Web-based quality
improvement training and a comparative study of accuracy of immunohistochemical tests of breast cancer
biomarkers between a well-established laboratory in the United States (University of Chicago) and a ﬁeld
laboratory in Ibadan, Nigeria. Two hundred and thirty-two breast tumor blocks were evaluated for estrogen
receptors (ERs), progesterone receptors (PRs), and HER2 status at both laboratories using tissue microarray
technique. Initially, concordance analysis revealed κ scores of 0.42 (moderate agreement) for ER, 0.41
(moderate agreement) for PR, and 0.39 (fair agreement) for HER2 between the 2 laboratories. Antigen
retrieval techniques and scoring methods were identiﬁed as important reasons for discrepancy. Web-based
conferences using Web conferencing tools such as Skype and WebEx were then held periodically to discuss
IHC staining protocols and standard scoring systems and to resolve discrepant cases. After quality assurance
and training, the agreement improved to 0.64 (substantial agreement) for ER, 0.60 (moderate agreement)
for PR, and 0.75 (substantial agreement) for HER2. We found Web-based conferences and digital
microscopy useful and cost-effective tools for quality assurance of IHC, consultation, and collaboration
between distant laboratories. Quality improvement exercises in testing of tumor biomarkers will reduce
misclassiﬁcation in epidemiologic studies of breast cancer subtypes and provide much needed capacity
building in resource-poor countries.ola).
Inc. Open access under CC BY-NC-SA license. ublished by Elsevier Inc. Open access under CC BY-NC-SA license. © 2013 The Authors. P1. Introduction
Breast cancer is the most prevalent cancer of women worldwide
[1,2]. Although breast cancer survival has improved over the past
decades in some developed countries [3], signiﬁcant differences in
breast tumor stage, treatment options, andmortality rates still exist inthe world with regard to race and ethnicity [2,4,5]. Despite the rapid
expansion of novel diagnostics designed to personalize breast cancer
care [6], there remain several signiﬁcant unmet needs for improving
the accuracy and reproducibility of tests that are already in common
daily clinical practice [7].
Over the past decades, breast tumor markers such as estrogen
receptor (ER), progesterone receptor (PR), human epidermal growth
factor receptor 2 (HER2) have become very useful in predicting
prognosis and determining therapy options for patients with breast
cancer. This has been particularly helpful in identifying those patients
who would beneﬁt from antiestrogen therapy and also those who
would likely respond to HER2-based therapy. The effective use of
Fig. 1. Photomicrographs of immunostained breast cancer whole sections from Ibadan
ER-positive case (A) and HER2-positive case (B).
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reliable, and reproducible determination of their presence and levels
in individual breast tumors.
Immunohistochemistry (IHC) has so far been used for ER, PR, and
HER2 determination. However, despite long-term use worldwide,
there still exists signiﬁcant intralaboratory and interlaboratory
variability of IHC results. Some identiﬁed reasons for interlaboratory
discrepancies include the following: type of antibody clone used,
differences in antigen retrieval techniques, formalin ﬁxation time, and
different scoring/reporting systems. As a result, an ad hoc consensus
conference, consisting of directors from a broad range of IHC
laboratories, was convened in 2006, which put together recommen-
dations aimed at standardizing IHC laboratory practices [8,9]. The
factors considered at the conference included preanalytic factors,
which focus on ﬁxation techniques; analytic factors, which talk about
antigen retrieval procedure; and postanalytic factors, which discuss
the scoring and reporting systems. Some of the speciﬁc recommen-
dations made at this conference include the exclusive use of formalin
ﬁxatives, the need for adequate ﬁxation time, careful selection of
antibody clone, and the use of an efﬁcient scoring system.
In Nigeria, IHC determination of breast tumor markers has just
recently been introduced. Only a handful of laboratories offer these
tests currently, and it is important to set up quality measures to
assure accurate performance of IHC analysis of breast tissues to guide
treatment decisions. The aim of this study therefore is to examine
the reproducibility of test results obtained from a ﬁeld laboratory
in Nigeria in comparison with data obtained from a well-
established laboratory at the University of Chicago, Illinois, using
tissue microarray (TMA) technology. We also assessed the
feasibility of Web-based conferences and digital microscopy in
ensuring quality assurance.
2. Materials and methods
2.1. Study settings
This studywas conducted at both the University of Chicago and the
Institute for Advanced Medical Research and Training (IAMRAT) at
Ibadan. It involved online IHC training sessions. The study was
approved by institutional review boards of the coordinating in-
stitutions in Ibadan and the University of Chicago [10]. After an initial
training (stage 1), the ﬁrst performance evaluation (stage 2) was
conducted followed by a review of process and then a session of
online training and discussion (stage 3) and a second evaluation of
performance (stage 4). Statistical analysis was performed with
StataSE software, version 10 (STATA, Cary, North Carolina). The κ
statistic served to test inter-tester agreement in IHC staining and
scoring. Overall inter-tester agreement was obtained based on κ
coefﬁcient calculated using a 4 × 4 weighting matrix.
3. Results
3.1. Initial training of personnel
A Nigerian pathologist (O.F.I.) obtained training at the Department
of Pathology of the University of Chicago. The training focused on IHC
testing techniques, antigen retrieval techniques, and handling red
ﬂags in IHC testing. The tests focused on ER, PR, and other
prognostically relevant biomarkers for breast cancer. After this
training program, he went back to the University of Ibadan to set up
an IHC laboratory within the IAMRAT and also train technical
personnel to man the laboratory. The necessary equipments needed
were shipped down to Nigeria from the United States, and these
included antibodies, ice racks, weighing equipment, and others. The
training session in Nigeria was an intensive course lasting 12 weeks.
Training sessions included seminars, use of academic literatures, andinvolved practical demonstrations giving opportunity for hands-on
experience. The training was extended to a laboratory technician at
IAMRAT and a board-certiﬁed pathologists from the University
College Hospital, Ibadan, Nigeria. After the training was completed,
information was sent to physicians and pathologists in hospitals
around the country through letters and e-mails informing them about
the commencement of IHC services in the laboratory. Immunohisto-
chemistry analysis for ER, PR, and HER2 of breast cancer tissues was
provided at no cost to referring physicians.
3.2. IHC testing in Ibadan
Samples of breast cancer cases from various teaching hospitals in
Nigeria were referred to the IAMRAT Laboratory at the University of
Ibadan for IHC analysis. Pathologists from the various referring
institutions were requested to send 2 formalin-ﬁxed tumor tissue
blocks and ﬁll in a laboratory consultation form detailing patients
biodata, clinical and pathologic information, and diagnosis. Four-
micron-thick sections were prepared using a Rotary microtome
machine from each of 235 formalin-ﬁxed, parafﬁn-embedded (FFPE)
tissue blocks received in the IAMRAT Laboratory representing 165
patients in all. These were subjected to immunohistochemical
analysis for ER, PR, and HER2 status (Fig. 1). The stained slides were
then scored by the pathologist based in Ibadan (O.A.O.) using the Dako
ER/PR pharmDx Interpretation Manual (Carpinteria, CA).
3.3. Construction of TMAs in Chicago
Tissue microarrays were successfully constructed in Chicago from
232 tumor samples of the total 235 FFPE blocks received from Nigeria.
Cores were precisely arrayed into a new recipient parafﬁn block using
the automated tissue microarrayer ATA-27 (Beecher Instruments, Sun
Prairie, Wisconsin), with the method described by Kononen et al [11].
Three tissue blocks were excluded because of small biopsy sample or
low tissue quality.
3.4. Immunohistochemistry testing in Chicago
Parafﬁn specimens were cut into 4-μm sections and mounted on
positively charged slides. The sections were deparafﬁnized and
rehydrated in xylene and then decreasing grades of alcohol
respectively and were then washed in Tris-buffered saline. Immuno-
histochemical assays were performed manually in the Ibadan
laboratory using standardized conditions with antibodies, antigen
unmasking, and scoring systems, as detailed in Table 1. Slides were
incubated in 0.03% hydrogen peroxide for 5 minutes to block
endogenous peroxidase activity, followed by incubation for 20
minutes in a protein-blocking solution (Protein Block Serum-free
solution; DAKO) to reduce nonspeciﬁc background. Envision +:
Table 1
Antibodies and conditions used for immunohistochemical analyses [12–14]
Antibody Clone Dilution Source Pretreatment Scoring
ER 1D5 1:50 Dako Microwave 30 min, citrate buffer (pH 6.0) Nuclear; 0, ≤10%; 1, 11%-30%; 2, 30%-70%; 3, ≥70% (13)
PR 636 1:50 Dako Microwave 30 min, citrate buffer (pH 6.0) Nuclear; 0, ≤10%; 1, 11%-30%; 2, 30%-70%; 3, ≥70% (13)
HER2 HercepTest Ready to use Dako Microwave 15 min, Epitope retrieval
solution (HercepTest catalog no. K5207)
Membranous; 0, 1+, 2+, 3+ (17)
Vimentin V9 1:50 Dako None Staining to monitor the quality of tissue ﬁxation in
archival tumors (12)
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treated for 5 minutes with 3-3′-diaminobenzidine chromogen,
counterstained with hematoxylin, and coverslipped. Appropriate
negative controls for the immunostaining were prepared by omitting
the primary antibody step.
3.5. First evaluation of immunostainings
The results of immunostainings for ER and PR were scored
semiquantitatively, independently by the 2 study pathologists
(A.I.K., O.A.O.) at the 2 study centers using 4-point scale of Reiner et al
[12] based on the intensity and percentage of IHC reaction. Regarding
staining with vimentin, V9 served as a control to monitor the quality of
tissue ﬁxation in archival tumors [13].
3.6. Initial concordance analysis
An initial concordance analysis was performed comparing IHC
results from the Nigerian laboratory, which used whole sections, with
corresponding IHC results from the Chicago laboratory derived from
TMAs. The IHC test results for ER and PR from Nigeria were initially
scored into 5 categories based on percentage and intensity of IHC
reaction (Dako ER/PR pharmDx Interpretation Manual) [15], whereas
in Chicago, the results were scored using the 4-point scale of Reiner et
al [12]. For the purpose of comparison, we used the conversion table
proposed by Shousha [16]. Assessment of HER2 status was performed
according to recommendations of the American Society of Clinical
Oncology and College of American Pathologists [17]. For this
concordance analysis, we had 155 comparable ER results, 164
comparable PR results, and 154 comparable HER2 results. The κ for
ER results was 0.42, which indicates a moderate agreement. The PR
results had a similar concordance with a κ of 0.41. The HER2 test
results had a κ of 0.38, which demonstrates a fair agreement.
3.7. Process review and Web-based training
In this stage, 23 digital microscopic images of randomly selected
cases were taken by the histotechnologist in Ibadan from the study
histologic slides with appropriate positive and negative controls for ER,
PR, and HER2 markers using a digital camera, which was mounted on a
microscope. The images were then transmitted in JPEG format over the
Internet as e-mail attachments to the pathologist in Chicago. The
images were reviewed by the pathologists in Chicago for scoring, image
quality, and staining characteristics using free graphic software Picasa
from Google and ImageScope, Aperio Technologies (Vista, CA). The
imageswere then jointly reviewed by both pathologists during theWeb
conferences. The purpose of this stagewas to assess the quality of digital
images and staining techniques in Nigeria and further train the
attending pathologist at the Ibadan ﬁeld IHC laboratory on techniques
of assessment of staining quality and scoring.
Tissue microarray slides created at the University of Chicago were
also scanned using Automated Cellular Imaging System (Fig. 2).
Digital images of discordant cases were then jointly reviewed online
by pathologists using freely downloadable viewing software Image
Scope Viewer (Aperio Technologies) and WebEx, a virtual meeting
manager that enabled us to share desktops, presentations, and imagesin real time. Web-based conferences were held biweekly, during
which we discussed IHC staining protocols, standardized scoring
systems, and resolved discrepant cases.
Interlaboratory Web-based conferences were performed using
user-friendly Web-based tools such as Skype and WebEx. Skype is a
software that enables one to make Internet calls free between users
who have Internet access. WebEx is an online conferencing tool that
enables conferencing from different physical location. It permits
desktop sharing and thus permits off-site presentations and facilitates
effective participation among the participants. The conferences were
held from 2 locations, one at IAMRAT, Ibadan, Nigeria, and another at
the University of Chicago in Illinois.
Some of the important reasons for the discrepancies identiﬁed
during the Web conference training sessions include differences in
staining protocols, antigen retrieval procedures, and scoring methods.
After the Web-based discussion sessions, joint evaluation of digital
slide images revealed almost complete agreement between both
pathologists. In addition to reviewing images, technical issues relating
to preanalytical, analytical, and postanalytical concept of IHC staining
and testing were discussed, such as follows:
• Duration of formalin ﬁxation of tissue
• Type of buffer used—commercial citrate vs locally prepared
• Choice of antibody clone used
• Antigen retrieval procedure—how long did they apply primary
antibody
• Type of diluent used
• Dilution ratio
• Scoring systems—percentage vs intensity of staining
3.8. Second evaluation of immunostainings
After the Web-based training, unstained TMA slides of all the
patients were then sent back to the laboratory at IAMRAT, Ibadan,
where they were restained and evaluated immunohistochemically for
ER, PR, and HER2, taking into cognizance all experiences acquired
during the Web-based training. Results were e-mailed to the
pathologist in Chicago for second concordance analysis. The concor-
dance level was then assessed again for evidence of improved staining
quality and scoring accuracy to assess the effectiveness of the online
training. In the ﬁnal evaluation after the Web conferences, the
concordance between TMA slides in Chicago and TMA slides restained
in Nigeria was shown to have improved with a κ of 0.64 (substantial
agreement) for ER results, 0.60 (moderate agreement) for PR, and 0.75
(substantial agreement) for HER2 results (see Table 2).
4. Discussion
Our study incorporated both the use of digitized images takenwith
a digital camera by the technologists at a Nigerian laboratory and
whole-slide imaging using Image Scope Aperio Technology in the
University of Chicago laboratory for quality assurance of IHC tests.
These digital images alongwith theWeb-based conferences proved to
be useful and cost-effective tools for long-distance training and
pathology consultations, especially in developing countries with
limited access to information, skilled specialists, and resources. This
Fig. 2. View of the Automated Cellular Imaging System shows breast cancer TMA cores immunostained with HER2/neu.
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images and thus resolve discrepant cases and was further conﬁrmed
by an overall improvement in the concordance results during the
second evaluation, which compared results from TMAs in Chicago
with results of TMA slides restained and scored in Nigeria.
Similar beneﬁts have been reported in other studies using Web-
based tools for pathology consultation. A pilot project between the
Italian hospital in Cairo, Egypt, and Civico hospital in Palermo
reported beneﬁts in costs reduction and ability to exchange
knowledge of high scientiﬁc value, ultimately leading to better
medical services through the use of static and dynamic techniques
of telepathology [18]. This study, like ours, demonstrated the
usefulness of simple Web-based conferencing tools such as Skype
and MSN for analyzing digital images in off-site pathology consulta-
tions [19]. Another study conducted in the Mohs surgical laboratory
compared the pathologic diagnosis between video images and
conventional light microscopy [20]. This study used off-the-shelf
consumer products like a digital video camera mounted on a
microscope to transmit images from the Mohs surgery suite to a
consultant viewing station off-site where the images were reviewed
via iChat AV on a computer by a dermatopathologist. The Mohs
laboratory group reported complete agreement between the iChat AV
dynamic telepathology diagnosis and conventional light microscopy
diagnosis for frozen section slides and 95% agreement for FFPE slides.
These results further conﬁrmed the potentials we found in the use of
virtual images for pathologic consultation. However, in addition, we
were able to demonstrate the use of these online tools in training local
pathologists with demonstrable improvement in antigen retrieval,
staining, and scoring techniques. In more advanced centers, high-
speed, automated whole-slide imaging systems are being used to
generate digital images of sufﬁcient quality for pathologists to make
reliable diagnostic decisions [21].Themajor challenges encountered included poor quality of some the
images from Nigeria and the relatively unstable Internet connection in
Nigeria. Some of the images taken at Ibadan contained artifacts, and
some had shadows cast on them possibly because of poor lighting and
inadequate focus. Achieving excellent image quality is essential for
virtual microscopy. Images should generally be at a sufﬁciently high
resolution, well focused over the entire slide, accurately represent the
colors exhibited on the glass specimen, reﬂect the representative area of
tumor, and be free of compression and other image artifacts. The
resolution of the images was, however, generally adequate for
evaluation by our pathologists. The high level of agreement between
both pathologistswhile reviewing the digital images online revealed the
potentials of the use of virtual images for pathologic consultation and
diagnosis. The ﬁndings thus support a need for enhanced medical
photography and telepathology as a cost-effective means of determi-
nation of interlaboratory variability of IHC testing and Web-based
quality improvement training and validation studies.
For our initial evaluation of concordance, we compared IHC scores
reviewed from whole slides in Nigeria with the scores reviewed from
TMAs in Chicago. We realize that the use of different technologies by
both laboratories could be partly responsible for the poor results in
the initial concordance analysis, but joint review of the images also
revealed other reasons for discrepancies. These issues were discussed,
and both pathologists agreed on ideal protocols and recommenda-
tions were made to the Nigerian laboratory. The improvement in
results of the ﬁnal concordance analysis is evidence of the success and
usefulness of theWeb conferences. For this analysis, we compared the
results from Chicago with results from TMA slides sent from Chicago
but restained and scored by the pathologists in Nigeria.
Furthermore, the signiﬁcance of this study can also be viewed
based on the therapeutic implications to the patients. Of 121
individual patients with breast cancer who had evaluable ER and/or
Table 2
Initial and ﬁnal concordance analysis comparing results from Nigeria with those from
TMAs in Chicago
ER results from Nigeria Total κ Value
0 1 2 3
ER results from Chicago 0 109 0 2 0 111
133 5 0 0 138
1 3 1 2 0 6
5 1 1 0 7
2 6 0 3 0 9
3 0 4 0 7
3 1 1 1 0 3
0 0 1 2 3
Total 119 2 8 0 129 0.42
141 6 6 2 155 0.64
PR results from Nigeria Total κ Value
0 1 2 3
PR results from Chicago 0 111 4 3 0 118
121 8 3 0 132
1 9 3 4 0 16
5 6 5 1 17
2 6 1 3 2 12
2 2 6 2 12
3 0 2 0 0 2
1 0 0 2 3
Total 126 10 10 2 148 0.41
129 16 14 5 164 0.60
HER2 results from
Nigeria
Total κ Value
0 1 2 3
HER2 results from Chicago 0 68 14 11 5 98
113 5 0 0 118
1 1 2 10 1 14
6 4 2 3 15
2 1 1 1 2 5
1 5 1 0 7
3 2 1 1 7 11
1 0 0 13 14
Total 72 18 23 15 128 0.39
121 14 3 16 154 0.75
Values for ﬁnal concordance comparing results from restained TMA slides in Nigeria
with results from TMAs in Chicago are in bold font.
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Chicago but were not found to be positive after the initial testing in
Nigeria based on a cutoff of 10% for both ER and PR positivities.
Likewise, there were 10 individual cases that were detected as PR
positive in Chicago but not found to be PR positive after the ﬁrst
testing in Nigeria. Therefore, based on the American Cancer Society
guidelines that assign hormone treatment based on ER and/or PR
positivity, 11 patients would have missed tamoxifen treatment based
on the ﬁrst evaluation of hormone receptors in Nigeria [22]. However,
6 of these 11 patients were later determined to be ER and/or PR
positive after the ﬁnal evaluation in Nigeria. Likewise, 10 of 124
individual patients were determined to be HER2 positive by the
Chicago laboratory but not by the initial evaluation in the Nigeria
laboratory. Five of them, however, were later determined to be HER2
positive after the ﬁnal evaluation in Nigeria. These results further
demonstrate the effect of our Web-based training in resolving at least
50% of discordant cases who would otherwise have missed vital,
proven adjuvant breast cancer therapy [22,23].
Consistent with previous studies [24,25], we also showed that TMA
use is an efﬁcient and cost-effective tool for quality assurance and for
assessing interlaboratory variability of IHC testing. Tissue microarrays
allow researchers to validate new biomarkers or to discover and
dissect molecular pathways, simultaneously, in hundreds of samples
and was therefore very adequate for our study [26]. This has
signiﬁcant cost reduction beneﬁts considering the high costs ofantibodies, which would have otherwise been used to process each
slide individually. Tissue microarray technology is, however, not yet
being used conventionally in Nigerian laboratories possibly because of
the initial high setup costs.
In summary, we have demonstrated the effectiveness of using simple
and easily accessible Web-based tools for pathology consultation in
different countries. We also showed that Skype and WebEx can be very
useful tools for online conferencing and image sharing. In the near future,
we hope to perform further concordance studies under similar standard
conditions using prospective tissue samples received at the laboratory in
Ibadan. These would further conﬁrm the effectiveness of our training
sessions. Accurate determination of breast cancer tumor markers has
signiﬁcant prognostic and therapeutic implications, so we recommend
that validation studies such as these be performed in emerging
laboratories and that virtual microscopy be used more to promote better
collaboration between pathologists in distant laboratories.
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